Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsBrian R. Murphy, Robert M. Chanock, James E. Crowe, Jr., Mark Connors
Estimating the term…
The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.
An immunogenic composition comprising, in a physiologically acceptable carrier, at least one attenuated respiratory syncytial virus having at least two attenuating mutations, which is a temperature-sensitive mutant of a host range-restricted cold-passaged respiratory syncytial virus.
A method for stimulating the respiratory syncytial virus specific immune response, which comprises administering to an individual an immunologically sufficient amount of at least one attenuated virus which is a temperature-sensitive mutant of a host range-restricted cold-passaged respiratory syncytial virus in a physiologically acceptable carrier.
Dependencies are inferred from the claim text.